Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes.
Pierre FenauxUwe PlatzbeckerGhulam J MuftiGuillermo Garcia-ManeroRena BucksteinValeria SantiniMaría Díez-CampeloCarlo FinelliMario CazzolaOsman IlhanMikkael A SekeresJosé F FalantesBeatriz ArrizabalagaFlavia SalviValentina GiaiParesh VyasDavid BowenDominik SelleslagAmy E DeZernJoseph G JurcicUlrich GermingKatharina S GötzeBruno QuesnelOdile Beyne-RauzyThomas CluzeauMaria-Teresa VosoDominiek MazureEdo VellengaPeter L GreenbergEva Hellström-LindbergAmer M ZeidanLionel AdèsAmit VermaMichael R SavonaAbderrahmane LaademAziz BenzohraJennie ZhangAnita RampersadDiana Ronai DunsheePeter G LindeMatthew L ShermanRami S KomrokjiAlan F ListPublished in: The New England journal of medicine (2020)
Luspatercept reduced the severity of anemia in patients with lower-risk myelodysplastic syndromes with ring sideroblasts who had been receiving regular red-cell transfusions and who had disease that was refractory to or unlikely to respond to erythropoiesis-stimulating agents or who had discontinued such agents owing to an adverse event. (Funded by Celgene and Acceleron Pharma; MEDALIST ClinicalTrials.gov number, NCT02631070; EudraCT number, 2015-003454-41.).